Exicure, Inc. to Present at the 2018 JMP Securities Life Sciences Conference on June 21st at 11:00 a.m. EDT

SKOKIE, Ill.--()--Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the JMP Securities Life Sciences Conference on Thursday, June 21st, 2018 at 11:00 a.m. EDT in New York City at The St. Regis New York.

A live webcast of the presentation will be available on the Events & Presentations section of Exicure's website, where it will also be archived and available for replay following the presentation for 30 days.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Exicure is based outside of Chicago, IL. For more information, please visit www.exicuretx.com.

Forward Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company's technology, potential therapies, pre-clinical results, and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: that Exicure's pre-clinical programs do not advance into the clinic or result in approved products on a timely or cost effective basis or at all; regulatory developments; and the ability of Exicure to obtain sufficient funding for its programs and to protect its intellectual property rights. Exicure's pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. Risks facing the Company and its programs are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Media Contact
Exicure, Inc.
Karen Sharma, 781-235-3060
ksharma@macbiocom.com
or
Investor Contact
The Del Mar Consulting Group, Inc.
Robert B. Prag, 858-794-9500
President
bprag@delmarconsulting.com

Recent Stories

RSS feed for Exicure, Inc.

Release Summary

Exicure, Inc. to Present at the 2018 JMP Securities Life Sciences Conference on June 21st at 11:00 a.m. EDT

Exicure, Inc.